Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labo EuromedisFRA:61R -0.80%63 Debt-to-EBITDA is 4.79 as of Dec. 2025, which is 93% above its 10-year median of 2.48. GuruFocus rates FRA:61R with a GF Score™ of 63/100 and a GF Value™ of €4.51. The stock has 6 warning signs investors should review. Among 91 Medical Distribution companies, Labo Euromedis ranks worse than 82.42% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Labo Euromedis's Debt-to-EBITDA or its related term are showing as below:
FRA:61R'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -20.98 Med: 2.48 Max: 8.59
Current: 5.9
During the past 13 years, the highest Debt-to-EBITDA Ratio of Labo Euromedis was 8.59. The lowest was -20.98. And the median was 2.48.
FRA:61R's Debt-to-EBITDA is ranked worse than 82.42% of 91
companies
in the Medical Distribution industry
Industry Median: 2.29
vs FRA:61R: 5.90
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Labo Euromedis Debt-to-EBITDA Related Terms
Labo Euromedis Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:61R vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Labo Euromedis's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Labo Euromedis (FRA:61R) has a Debt-to-EBITDA of 4.79 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Labo Euromedis. This is 93% above median its historical median of 2.48. According to the industry distribution chart, Labo Euromedis ranks #75 out of 91 companies in the Medical Distribution industry, placing it in the top 82.4%.
Is Labo Euromedis' Debt-to-EBITDA too high?
Labo Euromedis' current Debt-to-EBITDA of 4.79 is 93% above median its 10-year median of 2.48. The Medical Distribution industry median Debt-to-EBITDA is 2.29. Labo Euromedis' value of 4.79 is 109.2% above this industry median. Based on the distribution chart, Labo Euromedis ranks #75 out of 91 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Labo Euromedis has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #75 out of 91 companies for Debt-to-EBITDA. This places Labo Euromedis in the lower half of its industry. The industry median Debt-to-EBITDA is 2.29. Labo Euromedis' value of 4.79 is 109.2% above this benchmark. While the company's 10-year median is 2.48 vs. the industry median of 2.29, Labo Euromedis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.29, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labo Euromedis's current Debt-to-EBITDA of 4.79 is 109.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Labo Euromedis. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current Debt-to-EBITDA is 4.79, which is 93% above median its own 10-year median of 2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Labo Euromedis (FRA:61R) has a current Debt-to-EBITDA of 4.79. The stock's GF Value™ is €4.51, compared to a current price of €4.96 — trading 10% above its estimated fair value. The current Debt-to-EBITDA is 4.79, which is 93% above median its 10-year median of 2.48 and 109.2% above the Medical Distribution industry median of 2.29. Labo Euromedis' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current Debt-to-EBITDA is 4.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (FRA:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.96 is trading 10% above its estimated GF Value™ of €4.51.
Key valuation signals for FRA:61R:
Debt-to-EBITDA: 4.79 (93% above median its 10-year median of 2.48)
GF Value™: €4.51 vs. price of €4.96 (10% above fair value)
Industry Position: 109.2% above the Medical Distribution median (#75 of 91)
No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
63GF Score
Get the complete analysis for FRA:61R
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61R has been successfully added to your 
